Loading
Leads the world's highest-volume breast cancer surgical unit and the FUTURE trial that treats triple-negative breast cancer by molecular subtype.
Zhi-Ming Shao is Professor of Breast Surgery and Director of the Department of Breast Surgery at Fudan University Shanghai Cancer Center, the world's highest-volume breast cancer surgical unit. His group defined the Fudan classification of triple-negative breast cancer into four molecular subtypes using genomic profiling and RNA sequencing, and tested subtype-directed therapy in the FUTURE umbrella trial, which produced response rates far above conventional chemotherapy in refractory disease. His publications include the molecular subtyping and genomic profiling study that exposed precision therapy strategies in triple-negative breast cancer, and the FUTURE phase 2 umbrella trial in heavily pretreated metastatic disease. His interests are subtyping, precision oncology and umbrella trials.
| Title | Journal | Year |
|---|---|---|
| Molecular subtyping and genomic profiling expose precision therapy strategies in triple-negative breast cancer | Cancer Cell | 2019 |
| Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial | Cell Research | 2023 |
| KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment | New England Journal of Medicine | 2019 |
| monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer | Journal of Clinical Oncology | 2020 |
| OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer | New England Journal of Medicine | 2021 |
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
The FUSCC cohort is the East Asian reference and the basis of the FUTURE subtype-guided umbrella trial; its LAR findings point to CDK4/6 and HER2-mutant strategies rather than PARP inhibitors for that subtype.
HER2-positive breast cancer is now routinely treated before surgery so that the pathology result can guide what comes after: patients with no residual cancer continue trastuzumab (with or without pertuzumab), while those with residual disease switch to T-DM1. This model of using the tumour's response as a test has since been copied in triple-negative and other cancers.
Shares Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies, Fudan University Shanghai Cancer Center, RNA sequencing & expression profiling, Triple-negative breast cancer (TNBC).
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
Shares Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies, Fudan University Shanghai Cancer Center.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).